Shimizu Jun, Yamano Yoshihisa, Kawahata Kimito, Suzuki Noboru
Department of Immunology and Medicine, and Division of Rheumatology and Allergology, Institute of Medical Science, St. Marianna University School of Medicine, Sugao 2-16-1, Miyamae-ku, Kawasaki, 216-8511 Japan.
BMC Rheumatol. 2020 Sep 11;4:41. doi: 10.1186/s41927-020-00141-8. eCollection 2020.
In patients with relapsing polychondritis (RP), organ involvement developed in those with progressive and/or long disease courses. For their management, elucidation of a subgroup suggesting disease progression is awaited.
We previously conducted a physician's questionnaire-based retrospective study to elucidate major clinical features of Japanese patients with RP. We here evaluated organ involvement at disease onset and at the last follow-up. We then counted cumulative numbers of involved organs at the last follow-up in 229 RP patients and compared them with involved organ numbers at disease onset, as possible indicators of disease progression. We assigned their prognosis at the last follow-up into "patient prognostic stages" from no medication (stage 1) to death (stage 5). We utilized nonparametric tests for group comparisons.
Involved organ numbers per-patient were 1.13 ± 0.03 at disease onset and 3.25 ± 0.10 at the last follow-up (disease duration was 4.69 ± 0.33 years), and increased along with the patient prognostic stages.At disease onset, 135 and 48 patients had auricular involvement (59% of 229 patients, defined as auricular-onset subgroup; AO) and respiratory involvement (21%, respiratory-onset subgroup; RO), respectively. 46 patients presented with other conditions (20%, miscellaneous-onset subgroup; MO) including CNS, ocular, and inner ear involvement, among others.RO patients showed worse (poorer) prognostic stages than AO patients. MO patients developed respiratory and/or auricular involvement thereafter and then showed significantly higher mortality rate (15%; 7/46) than AO patients (5.9%; 8/135).In RP patients who did not develop respiratory involvement until the last follow-up (throughout the disease course; 117 patients), mortality rate was 19% in 26 MO patients and 3.3% in 91 AO patients. Accordingly, RO patients and MO patients associated with relatively poor prognosis compared with AO patients.
Allocation of patients to RO and MO subgroups was suggested to associate with poorer prognosis of RP than AO subgroups, especially AO subgroups without respiratory involvement throughout. All RP patients deserve careful monitoring but special attention should be paid to MO patients because of their diverse and accelerated disease progression.
在复发性多软骨炎(RP)患者中,器官受累发生于病程进展和/或较长的患者。对于其治疗,亟待明确提示疾病进展的亚组。
我们之前进行了一项基于医生问卷的回顾性研究,以阐明日本RP患者的主要临床特征。在此,我们评估了疾病发作时和最后一次随访时的器官受累情况。然后,我们统计了229例RP患者在最后一次随访时受累器官的累积数量,并将其与疾病发作时受累器官的数量进行比较,作为疾病进展的可能指标。我们将他们在最后一次随访时的预后分为“患者预后阶段”,从无需用药(1期)到死亡(5期)。我们采用非参数检验进行组间比较。
每位患者在疾病发作时受累器官的数量为1.13±0.03,在最后一次随访时为3.25±0.10(病程为4.69±0.33年),且随着患者预后阶段的增加而增加。在疾病发作时,分别有135例和48例患者出现耳部受累(229例患者中的59%,定义为耳部发作亚组;AO)和呼吸道受累(21%,呼吸道发作亚组;RO)。46例患者表现为其他情况(20%,杂项发作亚组;MO),包括中枢神经系统、眼部和内耳受累等。RO患者的预后阶段比AO患者差(更差)。MO患者此后出现呼吸道和/或耳部受累,然后显示出显著高于AO患者(5.9%;8/135)的死亡率(15%;7/46)。在直到最后一次随访(整个病程)都未出现呼吸道受累的RP患者(117例)中,26例MO患者的死亡率为19%,91例AO患者的死亡率为3.3%。因此,与AO患者相比,RO患者和MO患者的预后相对较差。
建议将患者分配到RO和MO亚组与RP比AO亚组更差的预后相关,尤其是整个过程中无呼吸道受累的AO亚组。所有RP患者都应接受仔细监测,但由于MO患者疾病进展多样且加速,应给予特别关注。